Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (132)	3/15/1999 11:28:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1834

Yes, melanocortin and its receptors are one of the central field in research for new obesity drug. But, I do not think that today investors in bt sector (except freaks from SI) are sufficiently motivated and capable to put two things together. Today reaction on BLSI news speak for itself. Unfortunately, I do not know (anyway need quick and broad update on all NBIX <+ few others CNS bts> programs) current NBIX position on melanocortin (after Northwest acquisition): patents, receptors right, ... MLNM and Stanford work confirm validity and promise of this research. Hope one day NBIX will have strong partner for this program. Miljenko